UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE TO
Tender Offer Statement under Section 14(d)(1) or 13(e)(1)
of the Securities Exchange Act of 1934
ANTARES PHARMA, INC.
(Name of Subject Company)
ATLAS MERGER SUB, INC.
a wholly owned subsidiary of
HALOZYME THERAPEUTICS, INC.
(Names of Filing Persons Offerors)
Common Stock, Par Value $0.01 Per Share
(Title of Class of Securities)
036642106
(Cusip Number of Class of Securities)
Mark Snyder
Senior Vice President, General Counsel and Corporate Secretary
Halozyme Therapeutics, Inc.
11388 Sorrento Valley Road
San Diego, California 92121
Telephone: (858) 794-8889
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)
Copies to:
Michael J. Aiello, Esq.
Sachin Kohli, Esq.
Weil, Gotshal & Manges LLP
767 Fifth Avenue
New York, New York 10153
(212) 310-8000
CALCULATION OF FILING FEE
Transaction Valuation* | Amount of Filing Fee* | |
N/A | N/A | |
|
* | A filing fee is not required in connection with this filing as it relates solely to preliminary communications made before the commencement of a tender offer. |
☐ | Check box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. |
Amount Previously Paid: Not applicable. | Filing Party: Not applicable. | |
Form or Registration No.: Not applicable. | Date Filed: Not applicable. |
☒ | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
Check the appropriate boxes below to designate any transactions to which the statement relates:
☒ | third-party tender offer subject to Rule 14d-1. |
☐ | issuer tender offer subject to Rule 13e-4. |
☐ | going-private transaction subject to Rule 13e-3. |
☐ | amendment to Schedule 13D under Rule 13d-2. |
Check the following box if the filing is a final amendment reporting the results of the tender offer. ☐
If, applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:
☐ | Rule 13e-4(i) (Cross-Border Issuer Tender Offer). |
☐ | Rule 14d-1(d) (Cross-Border Third-Party Tender Offer). |
This filing relates solely to preliminary communications made before the commencement of a tender offer by Atlas Merger Sub, Inc., a Delaware corporation (Purchaser) and a wholly owned subsidiary of Halozyme Therapeutics, Inc., a Delaware corporation (Halozyme), to acquire all of the outstanding shares of common stock of Antares Pharma, Inc., a Delaware corporation (the Company), to be commenced pursuant to an Agreement and Plan of Merger, dated as of April 12, 2022, by and among the Company, Halozyme and Purchaser.
Forward-Looking Statements
This communication contains forward-looking statements. All statements, other than statements of historical fact, included herein, including without limitation those regarding our future product development and regulatory events and goals, product collaborations, our business intentions and financial estimates and anticipated results, are, or may be deemed to be, forward-looking statements. Words such as expect, anticipate, intend, plan, believe, seek, estimate, think, may, could, will, would, should, continue, potential, likely, opportunity, project and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this communication. Although Halozymes and the Companys management each believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Halozyme and the Company, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, risks related to Halozymes and the Companys ability to complete the proposed acquisition on the proposed terms or on the proposed timeline, including the receipt of required regulatory approvals, the possibility that competing offers will be made, other risks associated with executing proposed acquisition, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the proposed acquisition will not be realized, risks related to future opportunities and plans for the combined company, including uncertainty of the expected financial performance and results of the combined company following completion of the proposed acquisition, disruption from the proposed acquisition making it more difficult to conduct business as usual or to maintain relationships with customers, employees, manufacturers or suppliers, and the possibility that, if the combined company does not achieve the perceived benefits of the proposed acquisition as rapidly or to the extent anticipated by financial analysts or investors, the market price of Halozymes shares could decline, as well as other risks related Halozymes and the Companys respective businesses, including the ability to grow sales and revenues from existing products and to develop, commercialize or market new products, competition, including potential generic competition, the uncertainties inherent in research and development, including future clinical data and analysis, regulatory obligations and oversight by regulatory authorities, such as the U.S. Food and Drug Administration, including decisions of such authorities regarding whether and when to approve any drug, device or biological application that may be filed for any product candidates as well as decisions regarding labelling and other matters that could affect the availability or commercial potential of any product candidates, the absence of a guarantee that any product candidates, if approved, will be commercially successful, Halozymes ability to execute its share repurchase program according to plan, Halozymes ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with Halozymes and the Companys intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on Halozyme and on the Company and their respective customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on Halozymes and the Companys employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact Halozyme and the Company. This situation is changing rapidly and additional impacts may arise of which Halozyme and the Company are not currently aware and may exacerbate other previously identified risks. While the list of factors presented here is representative, no list should be considered a statement of all potential risks, uncertainties or assumptions that could have a material adverse effect on Halozymes consolidated financial condition or results of operations. The foregoing factors should be read in conjunction with the risks and cautionary statements discussed or identified in the public filings with the U.S. Securities and Exchange Commission (the SEC) made by Halozyme, including those listed under Risk Factors and Cautionary Statement Regarding Forward-Looking Statements in Halozymes annual report on Form 10-K for the year ended December 31, 2021 and the Companys annual report on Form 10-K for the year ended December 31, 2021. The forward-looking statements speak only as of the date hereof and, other than as required by applicable law, Halozyme and the Company do not undertake any obligation to update or revise any forward-looking information or statements. Investors are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this communication.
About the Offer
The tender offer for the outstanding shares of Company common stock referenced in this communication has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities, nor is it a substitute for the tender offer materials that Halozyme and its acquisition subsidiary will file with the SEC, upon the commencement of the tender offer. At the time the tender offer is commenced, Halozyme and its acquisition subsidiary will file a tender offer statement on Schedule TO and thereafter the Company will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer.
THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WILL CONTAIN IMPORTANT INFORMATION. THE COMPANYS STOCKHOLDERS ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF THE COMPANYS SHARES SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES.
The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of the Companys stock at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement will be made available for free at the SECs website at www.sec.gov. Additional copies may be obtained for free by contacting Halozyme or the Company. Copies of the documents filed with the SEC by the Company will be available free of charge on the Companys internet website at https://www.antarespharma.com/investors/sec-filings or by contacting the Companys Investor Relations Department at +1 609-359-3016. Copies of the documents filed with the SEC by Halozyme will be available free of charge on Halozymes internet website at https://ir.halozyme.com or by contacting Halozymes Investor Relations Department at ir@halozyme.com.
Additional Information
In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Halozyme files annual, quarterly and special reports and other information with the SEC and the Company files annual, quarterly and special reports and other information with the SEC. You may read and copy any reports or other information filed by Halozyme and the Company at the SEC public reference room at 100 F. Street, N.E., Washington D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Halozymes and the Companys filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.
Exhibit No. | Description | |
(a)(5)(A) | Email to employees of Antares Pharma, Inc., dated April 13, 2022 | |
(a)(5)(B) | Email to employees of Halozyme Therapeutics, Inc., dated April 13, 2022 | |
(a)(5)(C) | Halozyme Therapeutics, Inc. employee FAQs, dated April 13, 2022 | |
(a)(5)(D) | Letter to partners of Halozyme Therapeutics, Inc., dated April 13, 2022 | |
(a)(5)(E) | Halozyme Therapeutics, Inc. infographic, published on April 13, 2022 | |
(a)(5)(F) | Social media posts (Twitter and LinkedIn) of Halozyme Therapeutics, Inc., dated April 13, 2022 | |
Exhibit (a)(5)(A)
To: Antares Employees
From: Helen Torley
Date: April 13, 2022
Subject: Welcome to the Halozyme Team
Dear Antares Team,
What an exciting day for both of our companies. On behalf of everyone at Halozyme, we couldnt be more excited for all that is ahead.
For those of you who may not be familiar with us, we are a biopharmaceutical company dedicated to bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. We are a diverse team, headquartered in San Diego and focused on bringing subcutaneous delivery options to patients through our ongoing collaborations and partnerships with 12 leading pharma and biotech companies. We are proud of our commercially validated ENHANZE drug delivery technology, which is used to facilitate the delivery of injected drugs and fluids and has the potential to significantly reduce treatment burden for patients.
We have long admired Antares and have a deep respect for its amazing team and your expertise and innovative pipeline. I have had the pleasure of spending significant time with your leadership team recently and it is clear to me that we share common goals when it comes to patient treatment opportunities. I believe that together we will be able to leverage deep industry expertise and existing commercial infrastructure to expand our capabilities and pursue growth opportunities in connection with a much broader range of products. Using our shared values as a base and building off of our incredible combined talent pool, I have no doubt that we will achieve great things together.
I look forward to meeting you in person soon talking further about what I believe is our exciting future together.
Sincerely,
Helen Torley
Chief Executive Officer and President, Halozyme
About the Offer
This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities, nor is it a substitute for the tender offer materials that Halozyme and its acquisition subsidiary will file with the SEC, upon the commencement of the tender offer. At the time the tender offer is commenced, Halozyme and its acquisition subsidiary will file a tender offer statement on Schedule TO and thereafter Antares will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer.
THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WILL CONTAIN IMPORTANT INFORMATION. ANTARES STOCKHOLDERS ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF ANTARES SHARES SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES.
The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of Antares stock at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement will be made available for free at the SECs website at www.sec.gov. Additional copies may be obtained for free by contacting Halozyme or Antares. Copies of the documents filed with the SEC by Antares will be available free of charge on Antares internet website at https://www.antarespharma.com/investors/sec-filings or by contacting Antares Investor Relations Department at +1 609-359-3016. Copies of the documents filed with the SEC by Halozyme will be available free of charge on Halozymes internet website at https://ir.halozyme.com or by contacting Halozymes Investor Relations Department at ir@halozyme.com.
Additional Information
In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Halozyme files annual, quarterly and special reports and other information with the SEC and Antares files annual, quarterly and special reports and other information with the SEC. You may read and copy any reports or other information filed by Halozyme and Antares at the SEC public reference room at 100 F. Street, N.E., Washington D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Halozymes and Antares filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.
Exhibit (a)(5)(B)
To: Halozyme Employees
From: Helen Torley
Date: April 13, 2022
Subject: Creating a Specialty Product and Drug Delivery Leader with Antares
Dear Colleagues,
I am writing to you all today to share some important news. Moments ago, we announced that Halozyme is acquiring Antares Pharma for $5.60 per share in cash. I am excited about what this means for Halozyme. With highly complementary science, products and capabilities, the combination of Halozyme and Antares will create a leading drug delivery and specialty product company. This is an important milestone for both of our companies, and you can read our joint announcement here <INSERT HYPERLINK>.
For those of you who may not be familiar with Antares, their business is a best-in-class, differentiated auto injector platform that offers broad licensing opportunity, and a commercial business, with three proprietary commercial products. In their work, they strive to positively affect patients lives by improving dosing, reducing side effects, and improving patient compliance and outcomes. When we initially began discussions with their team, I was struck by the similarities in our companys values and missions and saw an opportunity to augment our business in a meaningful way.
Before I dive into what this means for all of you, allow me to provide some additional color on this acquisition and the impact it will have on our business and our performance. This transaction will deliver immediate growth to Halozymes earnings (on a non-GAAP basis), enabling an acceleration of our value-driving strategy through 2027 and beyond. Halozyme will be able to offer even more opportunities for our team and benefits for patients, including:
| Immediate Growth and Long-Term Financial Upside: The addition of Antares is expected to immediately grow Halozymes revenue and non-GAAP earnings. |
| Substantial Market Expansion Opportunity: Antares successful commercial development and partnership of its auto injector technology platform offers a widely licensable product suite that can be broadly applied across high volume drugs and biologics when supported by Halozymes extensive infrastructure and experience, as well as our commercially validated ENHANZE platform technology. |
| Meaningful Pipeline Development: Antares brings to Halozyme three proprietary commercial products as well as a best-in-class, differentiated auto injector platform with broad licensing opportunities. Requiring no substantial customization, the platforms versatility will enable Halozyme to leverage our deep industry expertise and existing ENHANZE capabilities to expand our drug delivery capabilities and pursue new small- and large-molecule product opportunities. |
| Diversifies our Revenue Mix: The addition of Antares growing testosterone replacement anchors a commercial opportunity with key targeted audiences. |
We are approaching this acquisition from a position of strength and that is all thanks to the outstanding work that you all do every day. I am so proud of all that we have accomplished to date and I believe the addition of Antares will only create more opportunities for us to expand and grow into the future.
Our leadership team and I have spent significant time with the Antares team over the last several weeks, and it became clear that we share the common goal to create innovative solutions that address patient needs and improve their treatment experiences. Together we will be able to leverage deep industry expertise and existing commercial infrastructure in the U.S. to expand delivery capabilities and pursue growth opportunities in connection with a much broader range of products. With our shared values, and the incredible talent we are bringing together, I have great confidence in our ability to achieve our goal.
The transaction is anticipated to close in the first half of 2022. In the meantime, Halozyme and Antares will continue to operate as separate companies, and it is business as usual for us. While I anticipate much excitement about this transaction, I ask that you stay focused on your daily responsibilities and continue to deliver outstanding products and capabilities for patients.
As always, but especially during this time while the company has made public announcements about a transaction, please ensure your diligence in protecting the company from phishing attempts or other cyber-attacks.
I look forward answering your questions and discussing this announcement further at our companywide town hall meeting today at 9:00 a.m. Pacific Time, which you can access here <INSERT HYPERLINK>. I have also attached an FAQ that should address some of your initial questions.
We have so many exciting possibilities in front of us with the addition of Antares. I hope you feel as enthusiastic as I do about the future of Halozyme as we embark on our next chapter of accelerating financial growth, maximizing patient benefit, and enhancing value.
Thank you for all that you have achieved to get our Company to this point, and all that you will continue to do to ensure our future success.
Warm Regards,
Helen
Forward-Looking Statements
This communication contains forward-looking statements. All statements, other than statements of historical fact, included herein, including without limitation those regarding our future product development and regulatory events and goals, product collaborations, our business intentions and financial estimates and anticipated results, are, or may be deemed to be, forward-looking statements. Words such as expect, anticipate, intend, plan, believe, seek, estimate, think, may, could, will, would, should, continue, potential, likely, opportunity, project and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this communication. Although Halozymes and Antares management each believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Halozyme and Antares, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, risks related to Halozymes and Antares ability to complete the proposed acquisition on the proposed terms
or on the proposed timeline, including the receipt of required regulatory approvals, the possibility that competing offers will be made, other risks associated with executing proposed acquisition, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the proposed acquisition will not be realized, risks related to future opportunities and plans for the combined company, including uncertainty of the expected financial performance and results of the combined company following completion of the proposed acquisition, disruption from the proposed acquisition making it more difficult to conduct business as usual or to maintain relationships with customers, employees, manufacturers or suppliers, and the possibility that, if the combined company does not achieve the perceived benefits of the proposed acquisition as rapidly or to the extent anticipated by financial analysts or investors, the market price of Halozymes shares could decline, as well as other risks related Halozymes and Antares respective businesses, including the ability to grow sales and revenues from existing products and to develop, commercialize or market new products, competition, including potential generic competition, the uncertainties inherent in research and development, including future clinical data and analysis, regulatory obligations and oversight by regulatory authorities, such as the U.S. Food and Drug Administration, including decisions of such authorities regarding whether and when to approve any drug, device or biological application that may be filed for any product candidates as well as decisions regarding labelling and other matters that could affect the availability or commercial potential of any product candidates, the absence of a guarantee that any product candidates, if approved, will be commercially successful, Halozymes ability to execute its share repurchase program according to plan, Halozymes ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with Halozymes and Antares intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on Halozyme and on Antares and their respective customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on Halozymes and Antares employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact Halozyme and Antares. This situation is changing rapidly and additional impacts may arise of which Halozyme and Antares are not currently aware and may exacerbate other previously identified risks. While the list of factors presented here is representative, no list should be considered a statement of all potential risks, uncertainties or assumptions that could have a material adverse effect on Halozymes consolidated financial condition or results of operations. The foregoing factors should be read in conjunction with the risks and cautionary statements discussed or identified in the public filings with the U.S. Securities and Exchange Commission (the SEC) made by Halozyme, including those listed under Risk Factors and Cautionary Statement Regarding Forward-Looking Statements in Halozymes annual report on Form 10-K for the year ended December 31, 2021 and Antares annual report on Form 10-K for the year ended December 31, 2021. The forward-looking statements speak only as of the date hereof and, other than as required by applicable law, Halozyme and Antares do not undertake any obligation to update or revise any forward-looking information or statements. Investors are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this communication.
About the Offer
This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities, nor is it a substitute for the tender offer materials that Halozyme and its acquisition subsidiary will file with the SEC, upon the commencement of the tender offer. At the time the tender offer is commenced, Halozyme and its acquisition subsidiary will file a tender offer statement on Schedule TO and thereafter Antares will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer.
THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WILL CONTAIN IMPORTANT INFORMATION. ANTARES STOCKHOLDERS ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF ANTARES SHARES SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES.
The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of Antares stock at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement will be made available for free at the SECs website at www.sec.gov. Additional copies may be obtained for free by contacting Halozyme or Antares. Copies of the documents filed with the SEC by Antares will be available free of charge on Antares internet website at https://www.antarespharma.com/investors/sec-filings or by contacting Antares Investor Relations Department at +1 609-359-3016. Copies of the documents filed with the SEC by Halozyme will be available free of charge on Halozymes internet website at https://ir.halozyme.com or by contacting Halozymes Investor Relations Department at ir@halozyme.com.
Additional Information
In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Halozyme files annual, quarterly and special reports and other information with the SEC and Antares files annual, quarterly and special reports and other information with the SEC. You may read and copy any reports or other information filed by Halozyme and Antares at the SEC public reference room at 100 F. Street, N.E., Washington D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Halozymes and Antares filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.
Exhibit (a)(5)(C)
Employee FAQ
1. | What was announced? |
| We recently announced that Halozyme is acquiring Antares to create an industry-leading, drug delivery and specialty product company. |
| Both companies possess highly complementary science, products and capabilities, and, together, we will be able to offer even more opportunities for our team and benefits for patients. |
2. | Who is Antares? |
| Antares is a specialty pharmaceutical company headquartered in Ewing Township, New Jersey that combines drug and device development expertise with the direct promotion of three proprietary products and a proprietary auto injector delivery platform. |
| They have approximately 220 employees, with approximately 70 based in Minnesota, 30 in New Jersey and 120 field based. |
| Its products are designed to deliver meaningful advantages such as improved safety, efficacy, convenience and tolerability for enhanced patient comfort and adherence. |
| Antares and Halozyme have similar cultures and a shared mission to create innovative solutions that address patient needs and improve their treatment experiences. |
3. | Why is Halozyme Therapeutics acquiring Antares? How does this fit into Halozymes strategy? |
| The addition of Antares accelerates Halozymes strategy to create a leading position in drug delivery, and extends our strategy to include specialty products. |
| The combination diversifies our revenue, a key strategic goal, and provides substantial financial growth potential. |
| Together, we will embark on Halozymes next chapter of accelerating financial growth, maximizing patient benefit, and enhancing value for all stakeholders. |
4. | What does this mean for employees? |
| This transaction will create exciting opportunities for the combined company and thus for employees across both of our companies. |
| Together, we will be a drug delivery and specialty product leader, accelerating our strategy to drive long-term revenue growth. |
| We are optimistic that this transaction will create new and meaningful opportunities for employees development and career growth. |
| That said, until the transaction closes, it remains business as usual for all of us at Halozyme. |
5. | How does this announcement impact day-to-day responsibilities? |
| Until the closing of the transaction, Halozyme and Antares will continue to operate separately, and it is business as usual for us. |
| Your role will not change as a result of this transaction, although we are optimistic about the opportunities that lie ahead for both of our teams once the transaction is complete. |
| For now, I encourage you all to remain focused on your day-to-day responsibilities and continue to deliver for our partners and their patients. |
6. | When will the transaction be completed? What happens in the interim? |
| We anticipate the transaction will close in the first half of 2022. |
| In the meantime, Halozyme and Antares will continue to operate as separate companies. |
| We know this is an exciting announcement, but we ask that you stay focused on your daily responsibilities and continue to deliver outstanding products and capabilities for our partners and their patients. |
7. | What are the plans for integration? When does it begin? Who will lead it? |
| Todays announcement is just the first step toward bringing our businesses together and we will be developing integration plans over the coming weeks. |
| Well make additional decisions as we advance our integration planning and will keep you informed when and as there are updates to share. |
8. | How will employees be updated on the transaction and integration plans? |
| Todays announcement is just the first step toward bringing our companies together. |
| Well make additional decisions as we advance our integration planning and will keep you informed when and as there are updates to share. Certainly, we will update at our regular All- Hands meeting. |
9. | Will there be changes to the executive leadership team? Who will manage the combined business? |
| Helen will be the CEO of the combined company. |
| Todays announcement is just the first step toward bringing our companies together. Well make additional decisions as we advance our integration planning and will keep you informed when and as there are updates to share. |
10. | Will there be any layoffs as a result of this? Changes to compensation and benefits? |
| The two companies businesses are complementary and have little operational overlap. |
| Instead, this acquisition unites two strong industry leaders with proven capabilities to create a combined company that is more than the sum of its parts. |
| To fully realize this goal, our integration planning process will focus on maximizing the combined companys talent and resources. Both companies are committed to a smooth transition and we will update you as the process progresses. |
11. | What does this announcement mean for our business partners? |
| We believe that Antares auto injector technology is complementary to our ENHANZE technology, potentially allowing the injection of larger volumes of certain drugs subcutaneously, or to obtain faster injections. |
| Antares successful development and partnership of its technology platforms offers a widely licensable product suite that can be broadly applied across a spectrum of market segments representing tens of billions of dollars in estimated peak sales. |
| This includes the potential for conversion to both high-viscosity and high-volume auto injector devices, supported by Halozymes extensive infrastructure and commercially validated ENHANZE platform technology. |
12. | How soon can we interact with Antares employees? |
| Until the transaction closes, Halozyme and Antares will continue to operate separately, and we ask that you not connect with Antares employees unless you are asked to by your functional leader. |
13. | Will our company mission and culture stay the same? |
| Halozyme remains committed to significantly improving patient experiences and potential outcomes through innovative and disruptive solutions. |
| Antares shares that mission. |
14. | Where can I get additional information? |
| We will be holding a companywide town hall meeting today at 9:00 a.m. Pacific Time, where we look forward to answering your questions and discussing this announcement further. |
| We will also provide regular updates, including at our regular All-Hands meetings. |
15. | Who can I contact if I have more questions? |
| Should you have any additional questions, please reach out to your functional leader. |
| Its important to understand that we are only announcing the transaction today, and many of the details are still being finalized. |
| We will update you on our progress. |
Forward-Looking Statements
This communication contains forward-looking statements. All statements, other than statements of historical fact, included herein, including without limitation those regarding our future product development and regulatory events and goals, product collaborations, our business intentions and financial estimates and anticipated results, are, or may be deemed to be, forward-looking statements. Words such as expect, anticipate, intend, plan, believe, seek, estimate, think, may, could, will, would, should, continue, potential, likely, opportunity, project and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this communication. Although Halozymes and Antares management each believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Halozyme and Antares, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, risks related to Halozymes and Antares ability to complete the proposed acquisition on the proposed terms or on the proposed timeline, including the receipt of required regulatory approvals, the possibility that competing offers will be made, other risks associated with executing proposed acquisition, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the proposed acquisition will not be realized, risks related to future opportunities and plans for the combined company, including uncertainty of the expected financial performance and results of the combined company following completion of the proposed acquisition, disruption from the proposed acquisition making it more difficult to conduct business as usual or to maintain relationships with customers, employees, manufacturers or suppliers, and the possibility that, if the combined company does not achieve the perceived benefits of the proposed acquisition as rapidly or to the extent anticipated by financial
analysts or investors, the market price of Halozymes shares could decline, as well as other risks related Halozymes and Antares respective businesses, including the ability to grow sales and revenues from existing products and to develop, commercialize or market new products, competition, including potential generic competition, the uncertainties inherent in research and development, including future clinical data and analysis, regulatory obligations and oversight by regulatory authorities, such as the U.S. Food and Drug Administration, including decisions of such authorities regarding whether and when to approve any drug, device or biological application that may be filed for any product candidates as well as decisions regarding labelling and other matters that could affect the availability or commercial potential of any product candidates, the absence of a guarantee that any product candidates, if approved, will be commercially successful, Halozymes ability to execute its share repurchase program according to plan, Halozymes ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with Halozymes and Antares intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on Halozyme and on Antares and their respective customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on Halozymes and Antares employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact Halozyme and Antares. This situation is changing rapidly and additional impacts may arise of which Halozyme and Antares are not currently aware and may exacerbate other previously identified risks. While the list of factors presented here is representative, no list should be considered a statement of all potential risks, uncertainties or assumptions that could have a material adverse effect on Halozymes consolidated financial condition or results of operations. The foregoing factors should be read in conjunction with the risks and cautionary statements discussed or identified in the public filings with the U.S. Securities and Exchange Commission (the SEC) made by Halozyme, including those listed under Risk Factors and Cautionary Statement Regarding Forward-Looking Statements in Halozymes annual report on Form 10-K for the year ended December 31, 2021 and Antares annual report on Form 10-K for the year ended December 31, 2021. The forward-looking statements speak only as of the date hereof and, other than as required by applicable law, Halozyme and Antares do not undertake any obligation to update or revise any forward-looking information or statements. Investors are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this communication.
About the Offer
This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities, nor is it a substitute for the tender offer materials that Halozyme and its acquisition subsidiary will file with the SEC, upon the commencement of the tender offer. At the time the tender offer is commenced, Halozyme and its acquisition subsidiary will file a tender offer statement on Schedule TO and thereafter Antares will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer.
THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WILL CONTAIN IMPORTANT INFORMATION. ANTARES STOCKHOLDERS ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF ANTARES SHARES SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES.
The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of Antares stock at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement will be made available for free at the SECs website at www.sec.gov. Additional copies may be obtained for free by contacting Halozyme or Antares. Copies of the documents filed with the SEC by Antares will be available free of charge on Antares internet website at https://www.antarespharma.com/investors/sec-filings or by contacting Antares Investor Relations Department at +1 609-359-3016. Copies of the documents filed with the SEC by Halozyme will be available free of charge on Halozymes internet website at https://ir.halozyme.com or by contacting Halozymes Investor Relations Department at ir@halozyme.com.
Additional Information
In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Halozyme files annual, quarterly and special reports and other information with the SEC and Antares files annual, quarterly and special reports and other information with the SEC. You may read and copy any reports or other information filed by Halozyme and Antares at the SEC public reference room at 100 F. Street, N.E., Washington D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Halozymes and Antares filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.
Exhibit (a)(5)(D)
Creating a Specialty Product and Drug Delivery Leader with Antares
April 13, 2022
Dear [INSERT]:
Today, we announced that Halozyme is acquiring Antares Pharma, Inc. (Antares) to create a leading specialty product and drug delivery company. Together, we will be ideally positioned to achieve our common goal of developing innovative solutions that address patient needs and improve their treatment experiences.
As you may know, Antares is a specialty pharmaceutical company focused on the development and commercialization of its best-in-class, proprietary, high volume auto injector platform technology (2.25mL today with plans to develop a 5mL auto injector). We are enthusiastic about what this compelling combination of Antares and Halozyme will mean for all our stakeholders and the additional opportunities we can offer for our partners.
The transaction is anticipated to close in the first half of 2022. In the meantime, Halozyme and Antares will continue to operate as separate entities and it is business as usual for us. You should not expect any changes to how we work with you or deliver for patients. Please reach out to me or your Alliance Management team contact if you have any questions.
We look forward to building on our partnership and we thank you for your continued support.
Sincerely,
[Helen Torley
President and CEO
/ INSERT CUSTOMARY SIGNATOR]
Forward-Looking Statements
This communication contains forward-looking statements. All statements, other than statements of historical fact, included herein, including without limitation those regarding our future product development and regulatory events and goals, product collaborations, our business intentions and financial estimates and anticipated results, are, or may be deemed to be, forward-looking statements. Words such as expect, anticipate, intend, plan, believe, seek, estimate, think, may, could, will, would, should, continue, potential, likely, opportunity, project and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this communication. Although Halozymes and Antares management each believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Halozyme and Antares, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, risks related to Halozymes and Antares ability to complete the proposed acquisition on the proposed terms or on the proposed timeline, including the receipt of required regulatory approvals, the possibility that
competing offers will be made, other risks associated with executing proposed acquisition, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the proposed acquisition will not be realized, risks related to future opportunities and plans for the combined company, including uncertainty of the expected financial performance and results of the combined company following completion of the proposed acquisition, disruption from the proposed acquisition making it more difficult to conduct business as usual or to maintain relationships with customers, employees, manufacturers or suppliers, and the possibility that, if the combined company does not achieve the perceived benefits of the proposed acquisition as rapidly or to the extent anticipated by financial analysts or investors, the market price of Halozymes shares could decline, as well as other risks related Halozymes and Antares respective businesses, including the ability to grow sales and revenues from existing products and to develop, commercialize or market new products, competition, including potential generic competition, the uncertainties inherent in research and development, including future clinical data and analysis, regulatory obligations and oversight by regulatory authorities, such as the U.S. Food and Drug Administration, including decisions of such authorities regarding whether and when to approve any drug, device or biological application that may be filed for any product candidates as well as decisions regarding labelling and other matters that could affect the availability or commercial potential of any product candidates, the absence of a guarantee that any product candidates, if approved, will be commercially successful, Halozymes ability to execute its share repurchase program according to plan, Halozymes ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with Halozymes and Antares intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on Halozyme and on Antares and their respective customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on Halozymes and Antares employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact Halozyme and Antares. This situation is changing rapidly and additional impacts may arise of which Halozyme and Antares are not currently aware and may exacerbate other previously identified risks. While the list of factors presented here is representative, no list should be considered a statement of all potential risks, uncertainties or assumptions that could have a material adverse effect on Halozymes consolidated financial condition or results of operations. The foregoing factors should be read in conjunction with the risks and cautionary statements discussed or identified in the public filings with the U.S. Securities and Exchange Commission (the SEC) made by Halozyme, including those listed under Risk Factors and Cautionary Statement Regarding Forward-Looking Statements in Halozymes annual report on Form 10-K for the year ended December 31, 2021 and Antares annual report on Form 10-K for the year ended December 31, 2021. The forward-looking statements speak only as of the date hereof and, other than as required by applicable law, Halozyme and Antares do not undertake any obligation to update or revise any forward-looking information or statements. Investors are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this communication.
About the Offer
This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities, nor is it a substitute for the tender offer materials that Halozyme and its acquisition subsidiary will file with the SEC, upon the commencement of the tender offer. At the time the tender offer is commenced, Halozyme and its acquisition subsidiary will file a tender offer statement on Schedule TO and thereafter Antares will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer.
THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WILL CONTAIN IMPORTANT INFORMATION. ANTARES STOCKHOLDERS ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF ANTARES SHARES SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES.
The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of Antares stock at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement will be made available for free at the SECs website at www.sec.gov. Additional copies may be obtained for free by contacting Halozyme or Antares. Copies of the documents filed with the SEC by Antares will be available free of charge on Antares internet website at https://www.antarespharma.com/investors/sec-filings or by contacting Antares Investor Relations Department at +1 609-359-3016. Copies of the documents filed with the SEC by Halozyme will be available free of charge on Halozymes internet website at https://ir.halozyme.com or by contacting Halozymes Investor Relations Department at ir@halozyme.com.
Additional Information
In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Halozyme files annual, quarterly and special reports and other information with the SEC and Antares files annual, quarterly and special reports and other information with the SEC. You may read and copy any reports or other information filed by Halozyme and Antares at the SEC public reference room at 100 F. Street, N.E., Washington D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Halozymes and Antares filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.
Exhibit (a)(5)(E)
Halozyme to Acquire Antares to Create a Specialty Product and Drug Delivery Leader Expected to be Immediately Accretive to Revenue and Earnings Augments Drug Delivery Business with Best-in-Class Auto Injector Platform with Broad Licensing Potential Diversifies Revenue Mix with Addition of Three Commercial Products Targeting Key Audiences Immediate Revenue and Non-GAAP Earnings Accretion and Long-Term Financial Upside Expected to be immediately accretive to Halozymes revenue and non-GAAP earnings Generates additional cash flow, increasing Halozymes flexibility to pursue further growth drivers Business Development to Augment Long-Term Growth, Consistent with Strategic Priorities Antares commercial business and auto injector capabilities accelerate Halozymes strategy to drive long-term, durable revenue growth and value creation Halozyme expects to build on Antares core platform technology to drive incremental revenue opportunities with additional intellectual property protections beyond 2030 Substantial Market Expansion Opportunity in High Revenue Segments Antares auto injector technology platforms are widely licensable Halozymes extensive infrastructure and commercially validated ENHANZE platform technology supports conversion of Antares auto injector technology to high-viscosity and high-volume devices High Growth, Durable Commercial Franchise with Proven Track Record Antares portfolio of commercial and partner products have demonstrated commercial success and are positioned for long-term growth Launch of TLANDO will leverage Antares existing testosterone commercial infrastructure in a growing therapeutic category, building on momentum created by XYOSTED®s success Two Highly Complementary Platforms, Each with Meaningful Pipelines Antares broadly applicable, differentiated auto injector platform is suitable for use with a broad range of medications Transaction Terms $960M $5.60 Total transaction value Purchase price per share in cash Pathway to Close Expected to close in the first half of 2022 1H22 Closing is subject to the customary closing conditions and applicable regulatory approvals Halozymes commercially validated ENHANZE platform technology has 5 approved partner products and 14 partner products in development The acquisition of Antares fits well with our previously discussed strategic priorities and provides substantial financial growth potential and disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme is well-positioned to leverage Antares value proposition, driven by a strong balance sheet, established industry relationships and business development experience. We look forward to welcoming Antares talented team as we embark on our next chapter of accelerating financial growth, maximizing patient benefit, and enhancing value. Dr. Helen Torley, M.B. Ch. B., M.R.C.P., Chief Executive Officer of Halozyme. For more information visit: https://ir.halozyme.com/overview/default.aspx
Forward-Looking Statements This communication contains forward-looking statements. All statements, other than statements of historical fact, included herein, including without limitation those regarding our future product development and regulatory events and goals, product collaborations, our business intentions and financial estimates and anticipated results, are, or may be deemed to be, forward-looking statements. Words such as expect, anticipate, intend, plan, believe, seek, estimate, think, may, could, will, would, should, continue, potential, likely, opportunity, project and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this communication. Although Halozymes and Antares management each believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Halozyme and Antares, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, risks related to Halozymes and Antares ability to complete the proposed acquisition on the proposed terms or on the proposed timeline, including the receipt of required regulatory approvals, the possibility that competing offers will be made, other risks associated with executing proposed acquisition, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the proposed acquisition will not be realized, risks related to future opportunities and plans for the combined company, including uncertainty of the expected financial performance and results of the combined company following completion of the proposed acquisition, disruption from the proposed acquisition making it more difficult to conduct business as usual or to maintain relationships with customers, employees, manufacturers or suppliers, and the possibility that, if the combined company does not achieve the perceived benefits of the proposed acquisition as rapidly or to the extent anticipated by financial analysts or investors, the market price of Halozymes shares could decline, as well as other risks related Halozymes and Antares respective businesses, including the ability to grow sales and revenues from existing products and to develop, commercialize or market new products, competition, including potential generic competition, the uncertainties inherent in research and development, including future clinical data and analysis, regulatory obligations and oversight by regulatory authorities, such as the U.S. Food and Drug Administration, including decisions of such authorities regarding whether and when to approve any drug, device or biological application that may be filed for any product candidates as well as decisions regarding labelling and other matters that could affect the availability or commercial potential of any product candidates, the absence of a guarantee that any product candidates, if approved, will be commercially successful, Halozymes ability to execute its share repurchase program according to plan, Halozymes ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with Halozymes and Antares intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on Halozyme and on Antares and their respective customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on Halozymes and Antares employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact Halozyme and Antares. This situation is changing rapidly and additional impacts may arise of which Halozyme and Antares are not currently aware and may exacerbate other previously identified risks. While the list of factors presented here is representative, no list should be considered a statement of all potential risks, uncertainties or assumptions that could have a material adverse effect on Halozymes consolidated financial condition or results of operations. The foregoing factors should be read in conjunction with the risks and cautionary statements discussed or identified in the public filings with the U.S. Securities and Exchange Commission (the SEC) made by Halozyme, including those listed under Risk Factors and Cautionary Statement Regarding Forward-Looking Statements in Halozymes annual report on Form 10-K for the year ended December 31, 2021 and Antares annual report on Form 10-K for the year ended December 31, 2021. The forward-looking statements speak only as of the date hereof and, other than as required by applicable law, Halozyme and Antares do not undertake any obligation to update or revise any forward-looking information or statements. Investors are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this communication. About the Offer This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities, nor is it a substitute for the tender offer materials that Halozyme and its acquisition subsidiary will le with the SEC, upon the commencement of the tender offer. At the time the tender offer is commenced, Halozyme and its acquisition subsidiary will le a tender offer statement on Schedule TO and thereafter Antares will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WILL CONTAIN IMPORTANT INFORMATION. ANTARES STOCKHOLDERS ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF ANTARES SHARES SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of Antares stock at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement will be made available for free at the SECs website at www.sec.gov. Additional copies may be obtained for free by contacting Halozyme or Antares. Copies of the documents filed with the SEC by Antares will be available free of charge on Antares internet website at https://www.antarespharma.com/investors/ sec-filings or by contacting Antares Investor Relations Department at +1 609-359-3016. Copies of the documents filed with the SEC by Halozyme will be available free of charge on Halozymes internet website at https://ir.halozyme.com or by contacting Halozymes Investor Relations Department at ir@ halozyme.com. Additional Information In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/ Recommendation Statement, Halozyme files annual, quarterly and special reports and other information with the SEC and Antares files annual, quarterly and special reports and other information with the SEC. You may read and copy any reports or other information filed by Halozyme and Antares at the SEC public reference room at 100 F. Street, N.E., Washington D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Halozymes and Antares filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.
Exhibit (a)(5)(F)
Twitter Post
LinkedIn Post
Forward Looking Statements
This communication contains forward-looking statements. All statements, other than statements of historical fact, included herein, including without limitation those regarding our future product development and regulatory events and goals, product collaborations, our business intentions and financial estimates and anticipated results, are, or may be deemed to be, forward-looking statements. Words such as expect, anticipate, intend, plan, believe, seek, estimate, think, may, could, will, would, should, continue, potential, likely, opportunity, project and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this communication. Although Halozymes and Antares management each believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Halozyme and Antares, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, risks related to Halozymes and Antares ability to complete the proposed acquisition on the proposed terms or on the proposed timeline, including the receipt of required regulatory approvals, the possibility that competing offers will be made, other risks associated with executing proposed acquisition, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the proposed acquisition will not be realized, risks related to future opportunities and plans for the combined company, including uncertainty of the expected financial performance and results of the combined company following completion of the proposed acquisition, disruption from the proposed acquisition making it more difficult to conduct business as usual or to maintain relationships with customers, employees, manufacturers or suppliers, and the possibility that, if the combined company does not achieve the perceived benefits of the proposed acquisition as rapidly or to the extent anticipated by financial analysts or investors, the market price of Halozymes shares could decline, as well as other risks related Halozymes and Antares respective businesses, including the ability to grow sales and revenues from existing products and to develop, commercialize or market new products, competition, including potential generic competition, the uncertainties inherent in research and development, including future clinical data and analysis, regulatory obligations and oversight by regulatory authorities, such as the U.S. Food and Drug Administration, including decisions of such authorities regarding whether and when to approve any drug, device or biological application that may be filed for any product candidates as well as decisions regarding labelling and other matters that could affect the availability or commercial potential of any product candidates, the absence of a guarantee that any product candidates, if approved, will be commercially successful, Halozymes ability to execute its share repurchase program according to plan, Halozymes ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with Halozymes and Antares intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on Halozyme and on Antares and their respective customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on Halozymes and Antares employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could
2
also adversely impact Halozyme and Antares. This situation is changing rapidly and additional impacts may arise of which Halozyme and Antares are not currently aware and may exacerbate other previously identified risks. While the list of factors presented here is representative, no list should be considered a statement of all potential risks, uncertainties or assumptions that could have a material adverse effect on Halozymes consolidated financial condition or results of operations. The foregoing factors should be read in conjunction with the risks and cautionary statements discussed or identified in the public filings with the U.S. Securities and Exchange Commission (the SEC) made by Halozyme, including those listed under Risk Factors and Cautionary Statement Regarding Forward-Looking Statements in Halozymes annual report on Form 10-K for the year ended December 31, 2021 and Antares annual report on Form 10-K for the year ended December 31, 2021. The forward-looking statements speak only as of the date hereof and, other than as required by applicable law, Halozyme and Antares do not undertake any obligation to update or revise any forward-looking information or statements. Investors are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this communication.
About the Offer
This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities, nor is it a substitute for the tender offer materials that Halozyme and its acquisition subsidiary will file with the SEC, upon the commencement of the tender offer. At the time the tender offer is commenced, Halozyme and its acquisition subsidiary will file a tender offer statement on Schedule TO and thereafter Antares will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer.
THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WILL CONTAIN IMPORTANT INFORMATION. ANTARES STOCKHOLDERS ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF ANTARES SHARES SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES.
The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of Antares stock at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement will be made available for free at the SECs website at www.sec.gov. Additional copies may be obtained for free by contacting Halozyme or Antares. Copies of the documents filed with the SEC by Antares will be available free of charge on Antares internet website at https://www.antarespharma.com/investors/sec-filings or by contacting Antares Investor Relations Department at +1 609-359-3016. Copies of the documents filed with the SEC by Halozyme will be available free of charge on Halozymes internet website at https://ir.halozyme.com or by contacting Halozymes Investor Relations Department at ir@halozyme.com.
3
Additional Information
In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Halozyme files annual, quarterly and special reports and other information with the SEC and Antares files annual, quarterly and special reports and other information with the SEC. You may read and copy any reports or other information filed by Halozyme and Antares at the SEC public reference room at 100 F. Street, N.E., Washington D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Halozymes and Antares filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.
4
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
<&T3M)4Z:BJDH9+-O&A.)FR=:PRA^W5Y !IH'*(CK=GF5MUU-I(XP'[8\H
MF1"^=5 0N<7](G #Y;.^@58K249%]:G=1FY/7+P= <+5.XT"B
/)N]JY5VLNFN=97+X
M_KY6,F6KZ2>//L[[GF^)P3?"V+?0$'_@8 AS^UN4FKFN%R&J7D+7
MMH'>BD99SJ[%C6$Q2.WR6W60X+*7ZJQ4
1L!2S##6A]?\ 8H'INL74
MRC89P>%E79DJ7/&7W)\V6-=\!>NT,%N*HC31J+5;*.;;Z'L?0:>YFPRA<44L
M8S:^;,1JN_HOC;+]/>?_ *0/&X8RL.7^TGC>L<<5XN3O1/'32R- ^>S!9A#M
M6OE)67M:[Z(1@5EUL@N43)LG$B'.51Y3WEM'YBI:A"U3L_OU0G:/*
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M+C*[7_:#RL7S&SUXHMN-BAW)B=K'=M%F4>MZ66,HHGE&P!+%-9Q
M7;6VHY>VIICRA[1S@A<9#\_'HR:V>^E*(5P$._/5D8G,+O,I(,\I5AT Z#98
MC=J-LX]$U2 M=:L&U&G"SH*(VRJTN1H42"9V5D$=C 9/1WT(\MMH4C+73Y.&
ML'M"N5 4K0D;84]OZ
;TP## V:8PKN52V\RYI0;PM>HC.NI3(F'/XLC.ND,LS'8YTN\'^THZ$6'_>
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MB?\ 0M'Y;"F48W4FB,:U5WT+ ?:P9Q8MR>SN-J<7NUX[M.FIK> >;=M*O61=5NWQ+*6?;P$E=*Q5=HCDI4XE1KI@P(#G*<[+*?YB-:[EJO
M\S\G/;#FVY;+7MT9#YSR<*QXDCRVS ASH;V%5-D?[(.D:]L+OK)C,>\CG;>Q
M[./Y<%RXU_V:^J.47ZIRR19"I$/IH:QEQY;V]4I9H\EY^KNDKB3W\R$PZ7'H
M;[:(R)$C>&//^.2HJY4+W+MH(_7F13UL?@,"24:G*,>7E!"&V21G",J3RITVSN_K@,ZC3++YU
MQC$F^ZZV?9VSG/I+EI)O&?KAHL\L/18_$LT#!7_:6L@+.SX8 R;--;-AUA65
MPR\HMMLSRK";)])E)N5R4_Q+OC8+EMV>=^,QUF/Z^U:7TE%@\KB:
66O':EB
M%K$5"ID"I#O=YE^M8N"F:3S%Z%>.E,5T%+UMPWJ8,/[)DQX=LAV,?RE+G.%Q
MET ;[+>/DKF[;FA/H7I+:(&WF9K1B?E63Z,Q\F',%I(5UWE@W[U02%7="/83
MC5V^/>CRA;(E2Y8^^SW@&J(SE+#*M-1=2E(]"7%:WSD\,+(JQ+_/.K="RLTR
M?_)YRY^'Z.MO5W0%[V_L+JYSIMIG"):E=2/MQXF+_7_
SO>XK6K _/J3VI*1;_ +X<2HB'EK&C,?D!
MXDV1E;7=5=SGZ;86=&,O)GVY\/5VEC.GSE :L7&-'2_0931HV"08<=64'4S"
M9KA2*CG8[T&8(\(V7WQ-H[^//VP_D5+&']F/)=3KO.46=$:ZIOH]D5CJ&U68
M80!P>CEBMUICUKMX:#$),^ZIQ)5-@4+N$SK(JE_$JK8=F*E-T_9WR$APWSP[
MAN0\S[)@%H%0N9?EF(ERFA82RU;BH4"[_'8\&AT+VUC;V-%?;N1EWDN2Y$5+
M$I^TGC;>+KL'3Q=9G\^SUC,=UC=8H)AF52+-Z:YV/0